



COMPANY DESCRIPTION

FORMYCON is a leading and independent developer of high-quality biosimilars. The team of FORMYCON has extensive experience in complex biological molecules and is able to meet the high standards of the world's most stringently regulated markets: the European Union, the United States, Canada, Japan and Australia, through its particular expertise. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases. FORMYCON currently has four biosimilars in development. Two of them have already been licensed to Bioeq IP AG and Santo Holding GmbH while a third will be further developed in a joint venture with Aristo Pharma GmbH. Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets. Analysts expect worldwide biosimilar-revenue to grow up to USD 15 billion by the year 2020. This number could even double by the year 2025. Because of their size and structural complexity, and their production using living cell systems, biosimilars require very significant time, effort and expertise, both in their development and in their subsequent production.

PIPELINE	Reference Product Active Ingredient Disease Area	Indications	Partner	Preclinical Phase	Clinical Phase I	Clinical Phase III
FYB 201	Lucentis® Ranibizumab Ophthalmology	wAMD, DME, RVO, mCNV, DR*	Bioeq IP AG	✓	✓	✓
FYB 202	Stelara® Ustekinumab Immunology	Pso, PsA, CD, UC	Aristo Pharma GmbH		Phase I Start Oct. 19	
FYB 203	Eylea® Aflibercept Ophthalmology	wAMD, DME, RVO, DR*, mCNV**	Santo Holding GmbH		Phase III Start Mid 2020	
FYB 205	🔒	🔒				

* FDA approved only ** EMA approved only

STRATEGY & GOALS

FORMYCON is specifically concentrating on the "third wave" of biosimilars, namely follow-on products for blockbuster biopharmaceuticals with patent expiries beginning in the year 2020. Because FORMYCON has focused its efforts on this generation of biosimilars at a timely stage, the company has been able to carve out for itself a unique and leading position in this market space. It's the strategic goal to further strengthen that status and, as a leading independent developer of biosimilars, to assume a key role in this global market. FORMYCON strives to cover the entire value creation chain, from technical-pharmaceutical development to the clinical trials as well as the preparation of dossiers for marketing approval. Biosimilars are the drugs of the future. Through their proven efficacy, cost efficiency and high standard of quality, biosimilar medicines are already making a major contribution towards enabling patient access to effective medical treatments. Through its biosimilars, FORMYCON will help not only patients around the world but also contributes to ease the financial strains on the world's healthcare systems.

FACTS

Founded	2007
Headquarters	Planegg / Munich
Employees	> 100
Management	Dr. Carsten Brockmeyer (CEO) Dr. Nicolas Combé (CFO) Dr. Stefan Glombitza (COO)
Supervisory Board	Dr. Olaf Stiller (Chairman) Hermann Vogt (Deputy Chairman) Peter Wendeln (Member Supervisory Board)

KEY FINANCIALS (in € million)

	2016	2017	2018	2019e*
Revenue	19.5	29.4	43.0	38.0
Operating Income (EBIT)	-4.1	-1.5	7.1	-3.5
Net Income	-4.1	-1.6	7.1	-3.7
Equity Ratio (in %)	82.9	82.9	83.9	n.A.

* Analyst Forecast

HIGHLIGHTS 2019

NOV 2019	Bioeq IP exclusively licenses US Marketing Rights for FYB201 to Coherus BioSciences, Inc.
OCT 2019	Formycon announces Start of Phase I Clinical Trial with Ustekinumab Biosimilar Candidate FYB202
SEP 2019	Formycon Publishes Half-Year Results for 2019
JUN 2019	Formycon Reports Further Course of Capital Measure
JUN 2019	Formycon Reports Latest Status of Capital Increase
MAY 2019	Formycon Reports Successful 2018 Financial Year
MAY 2019	Formycon Announces News on Development Portfolio

FINANCIAL CALENDAR

Publication of Annual Report 2019	May 2020
Quarterly Statement Q1 / 2020	June 2020
Annual General Meeting 2020	June 30, 2020
Publication of Half-Year Report 2020	September 2020
Statement Nine-Month Figures 2020	November 2020

MARKET DATA

ISIN	DE000A1EWVY8
Market Segment	Frankfurt, Stock Exchange „Scale“
Market Capitalization	~ € 300 million
Outstanding Shares	10,000,000
Shareholder Structure	15 % Institutional Investors 35 % Family Offices 15 % Founders and Management 35 % Free Float